Sign up Australia
Proactive Investors - Run By Investors For Investors

Viralytics raising up to $27.1M to complete anti-cancer drug trials

Viralytics raising up to $27.1M to complete anti-cancer drug trials

Viralytics (ASX: VLA) is raising up to $27.1 million to complete three key clinical trials for its CAVATAK anti-cancer drug and to advance more rapidly to commercialisation.

It will also ensure the company is fully funded until the end of 2016 and strengthen its balance sheet ahead of potential commercial negotiations.

The funds will enable it to complete:

-    The Phase 2 CALM trial of CAVATAK in late stage melanoma patients;
-    Phase 1/2 STORM trial assessing the multiple intravenous dosing of CAVATAK™ in patients with solid tumours including melanoma, prostate, lung or metastatic bladder cancers due to commence in February 2014; and
-    Randomised Phase 2 trial in melanoma patients planned for commencement late 2014.

Viralytics has binding commitments to raise $23 million via a two tranche placement priced at $0.28 each to leading U.S. and UK –based specialist healthcare institutional investors.

It will also raise up to $4.1 million through a 1 for 6 non-renounceable entitlement offer at $0.28 per share.

The Placement and the Entitlement Offer price of $0.28 represents a 12.5% discount to the weighted average closing price for the fifteen trading days to 24 January 2014.

Earlier this month, the company achieved the target enrolment for the Phase 2 melanoma trial for CAVATAK in the treatment of late stage melanoma.

The 54th patient has been injected with the drug while interim results show that 14 of the 40 evaluable patients reaching the six month immune related Progression Free Survival target.

In addition, there is promising one year survival data with 12 of first 20 patients still alive at that stage.

Viralytics currently has a market capitalisation of $26.2 million.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

View full VLA profile View Profile

Viralytics Timeline

December 10 2015

Related Articles

September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients
consumer health segment overview
September 17 2018
The company sells clinically validated anti-ageing products for hair, skin and body.
Callitas CEO James Thompson
July 21 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use